| Autor: |
Mayor A; INSERM, Centre D'Etude Des Pathologies Respiratoires, Universite François Rabelais de Tours, 10 Boulevard Tonnellé, U1100F-37032, Tours, France.; University of Tours, Tours, France.; Sanofi, Formulation and Process Development, Impasse Des Ateliers, 94400, Vitry-sur-Seine, France., Thibert B; Sanofi, Formulation and Process Development, Impasse Des Ateliers, 94400, Vitry-sur-Seine, France., Huille S; Sanofi, Formulation and Process Development, Impasse Des Ateliers, 94400, Vitry-sur-Seine, France., Respaud R, Audat H; Sanofi, Formulation and Process Development, Impasse Des Ateliers, 94400, Vitry-sur-Seine, France., Heuzé-Vourc'h N; INSERM, Centre D'Etude Des Pathologies Respiratoires, Universite François Rabelais de Tours, 10 Boulevard Tonnellé, U1100F-37032, Tours, France. nathalie.vourch@med.univ-tours.; University of Tours, Tours, France. nathalie.vourch@med.univ-tours. |
| Abstrakt: |
Respiratory infections are life-threatening and therapeutic antibodies (Ab) have a tremendous opportunity to benefit to patients with pneumonia due to multidrug resistance bacteria or emergent virus, before a vaccine is manufactured. In respiratory infections, inhalation of anti-infectious Ab may be more relevant than intravenous (IV) injection-the standard route-to target the site of infection and improve Ab therapeutic index. One major challenge associated to Ab inhalation is to prevent protein instability during the aerosolization process. Ab drug development for IV injection aims to design a high-quality product, stable to different environment stress. In this study, we evaluated the suitability of Ab formulations developed for IV injection to be extended for inhalation delivery. We studied the aerosol characteristics and the aggregation profile of three Ab formulations developed for IV injection after nebulization, with two mesh nebulizers. Although the formulations for IV injection were compatible with mesh nebulization and deposition into the respiratory tract, the Ab were more unstable during nebulization than exposition to a vigorous shaking. Overall, our findings indicate that Ab formulations developed for IV delivery may not easily be repurposed for inhalation delivery and point to the requirement of a specific formulation development for inhaled Ab. |
Full text from SpringerLink